The short version of animal model fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-17. Anything still debated is marked as such rather than presented as settled.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
=== Pharmacodynamics === SR-17018 acts as a biased partial agonist of the μ-opioid receptor (MOR), with strong selectivity for activation of G protein signaling over β-arrestin2 recruitment. Its affinities (Ki) for the human opioid receptors have been reported to be 11 nM for the MOR, 68 nM for the κ-opioid receptor (KOR), and >10,000 nM for the δ-opioid receptor (DOR). In terms of MOR activation, the drug had activational potencies and efficacies (EC50Tooltip half-maximal effective concentration and EmaxTooltip maximal efficacy) of 97–193 nM (72–75%) for GTPγS binding, 76 nM (105%) for cAMPTooltip cyclic adenosine monophosphate accumulation, and >10,000 nM (10%) for β-arrestin2 recruitment. Both GTPγS binding and cAMP accumulation are measures of G protein signaling. The drug showed a calculated bias factor for GTPγS binding over β-arrestin2 recruitment of 80 to 100 relative to DAMGO. SR-17018 also showed strong bias for G protein activation over β-arrestin2 recruitment using mouse proteins, albeit with reduced efficacy for GTPγS binding (Emax = 37%). β-Arrestin2 activation may contribute to opioid tolerance, though it is not the only mechanism of tolerance to these drugs. SR-17018 shows a strikingly different MOR phosphorylation profile from other MOR biased, partial, and full agonists. Additional studies have characterized the interactions of SR-17018 with the MOR, including activational potencies and efficacies at downstream signaling pathways, as well.
The peaceful transition of power from Cardoso to his main opposition leader, Luiz Inácio Lula da Silva (elected in 2002 and re-elected in 2006), was seen as proof that Brazil had achieved a long-sought political stability. However, sparked by discontent accumulated over decades from corruption, police brutality, inefficiencies of the political establishment and public service, numerous peaceful protests erupted in Brazil in the middle of the first term of Dilma Rousseff, who had succeeded Lula after winning election in 2010 and again in 2014 by narrow margins. Rousseff was impeached by the Brazilian Congress in 2016, halfway into her second term, and replaced by her vice-president Michel Temer, who assumed full presidential powers after Rousseff's impeachment was accepted on 31 August. Large street protests for and against her took place during the impeachment process. The charges against her were fueled by political and economic crises along with evidence of involvement with politicians from all the primary political parties. In 2017, the Supreme Court requested the investigation of 71 Brazilian lawmakers and nine ministers of President Michel Temer's cabinet who were allegedly linked to the Petrobras corruption scandal. President Temer himself was also accused of corruption. In the fiercely contested 2018 elections, the controversial conservative candidate Jair Bolsonaro of the Social Liberal Party (PSL) was elected president, winning in the second round against Fernando Haddad, of the Workers Party (PT), with the support of 55.13% of the valid votes.
In addition, Greek authorities seized a 7,000 square-metre plot of land on Paros, Greece in the Cyclades islands, which had been purchased jointly by Kaili and Giorgi. As the European Parliament convened for the first time following the scandal, on 13 December 2022, at its seat in Strasbourg, France, the offices of MEP Pietro Bartolo and Parliamentary official Mychelle Rieu were sealed by investigators. On 15 December, the European Public Prosecutor's Office (EPPO) requested that the European Parliament lift the parliamentary immunity of Eva Kaili and her fellow Greek MEP Maria Spyraki. The EPPO explained that the request was based on an investigative report from the European Anti-Fraud Office (OLAF), regarding raised "suspicion of fraud detrimental to the EU budget, in relation to the management of the parliamentary allowance." The request particularly pertained to funds paid to parliamentary assistants. On 2 January 2023, Belgian investigators submitted a request to the European Parliament to strip MEPs Marc Tarabella and Andrea Cozzolino of their parliamentary immunity. A hearing of the Parliament's Legal Affairs Committee was scheduled during the parliamentary sitting in Strasbourg on 16 January, allowing the accused MEPs to present their defence. The parties of both Tarabella and Cozzolino expressed their support for President Metsola's requests to assist the European Public Prosecutor's Office in the investigations and agreed to vote in favour of waiving their immunity. On 2 February, the European Parliament approved the request to lift their immunity.
Sources: en.wikipedia.org
== Early political career == In 2019, Kiggans ran for the Virginia Senate for the 7th district, which was being vacated by Republican incumbent Frank Wagner. In the Republican Party primary, Kiggans defeated Virginia Beach School Board member Carolyn Weems, 52% to 48%. In the general election, Kiggans faced Democratic state Delegate Cheryl Turpin. The race was viewed as competitive, as the district had very narrowly favored Democrats in recent statewide elections. Kiggans and Turpin each spent over $500,000 on television advertisements. Kiggans won, 50.4% to 49.5%. The Washington Post reported that "Her record didn't always fit neatly along a party line." She voted to expand nondiscrimination protections for LGBTQ people and for environmental protection measures. In 2022, Kiggans introduced a bill to prohibit transgender girls from playing girls' sports and voted for an audit of the 2020 election.
=== Honours === House of Habsburg: Grand Mistress Dame of the Order of the Starry Cross Dame Grand Cross of the Order of Elisabeth, 1913 Knight Grand Officer of the Order of the Red Cross, with War Decoration Sovereign Military Order of Malta: Dame Grand Cross of Honour and Devotion of the Order of Saint John
The control of enzymatic browning has always been a challenge for the food industry. A variety of approaches are used to prevent or slow down enzymatic browning of foods, each method aimed at targeting specific steps of the chemical reaction. The different types of enzymatic browning control can be classified into two large groups: physical and chemical. Usually, multiple methods are used. The use of sulfites (powerful anti-browning chemicals) have been reconsidered due to the potential hazards that it causes along with its activity. Much research has been conducted regarding the exact types of control mechanisms that take place when confronted with the enzymatic process. Besides prevention, control over browning also includes measures intended to recover the food color after its browning. For instance, ion exchange filtration or ultrafiltration can be used in winemaking to remove the brown color sediments in the solution.
Sources: en.wikipedia.org
== Traffic congestion == TomTom, the Dutch manufacturer of land navigation products, ranked Bangkok as the second-most traffic-clogged city of 189 cities studied worldwide. Mexico City topped the rankings. Other ASEAN cities listed were Jakarta, third, and Singapore at 55. The INRIX 2016 Global Traffic Scorecard ranked Thailand as the most congested nation of 38 studied for "average peak hours spent in congestion". Thais spent an average of 61 hours in 2016 stuck in traffic. Bangkok was ranked 11 of 100 cities for "peak hours spent in congestion", 64 hours. Based on 2015 data, Dutch navigation and digital mapping company, TomTom NV, ranked Bangkok number two in a listing of the 174 most traffic congested cities worldwide (1=most congested; 174=least congested). Mexico City ranked number one. No other ASEAN cities made the list.
=== North America === In North America, medical physics training is offered at the master's, doctorate, post-doctorate and/or residency levels. A professional doctorate has also been recently introduced as an option. Several universities in Canada and the United States offer these degrees. As of October 2013, over 70 universities in North America have medical physics graduate programs or residencies that are accredited by The Commission on Accreditation of Medical Physics Education Programs (CAMPEP). The majority of residencies are therapy, but diagnostic and nuclear have also been on the rise in the past several years. In the United States, professional certification is obtained from the American Board of Radiology (for all 4 areas) the American Board of Medical Physics (for MRI), the American Board of Science in Nuclear Medicine (for Nuc Med and PET). As of 2012, enrollment in a CAMPEP-accredited residency or graduate program is required to start the ABR certification process. As of 2013, completion of a CAMPEP-accredited residency is required to advance to part 2 of the ABR certification process. In Canada, professional certification is obtained from the Canadian College of Physicists in Medicine (for all 4 areas and Mammography). Since 2016, eligibility requirements for Radiation Oncology Physics certification includes graduation and post-graduate training from a CAMPEP accredited institution.
The Penning ionization electron energy does not depend on the conditions of the experiments or any other species since both Em and IE are atomic or molecular constants of the energy of He* and the ionization energy for the species. Penning ionization electron spectroscopy applied to organic solids. It enables the study of local electron distribution of individual molecular orbitals, which exposes to the outside of the outermost surface layers.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.